Athenex: An Under-The-Radar Buying Opportunity

He previously founded and served as the CEO and chairman of Sagent Pharmaceuticals from 2007 until 2016. Yordon has a Bachelor of Science in political science from Northern Illinois University. 

Financials overview

For the year that ended on Dec. 31, 2016, the company reported $19,364,000 in product sales and total revenues of $20,551,000. For the year that ended on Dec. 31, 2015, the company reported $12,816,000 in product sales and total revenues of $13,944,000. Athenex reported net losses of $85,747,000 and $50,708,000 in 2016 and 2015, respectively. 

Athenex priced its shares at $11, which was the low end of its marketed range of $11 to $13. ATNX has performed well since its IPO in early trading and was most recently trading at $16 per share at market close on June 30, 2017. The company's underwriters exercised their over-allottment options in full during the IPO. 

Conclusion: New Chance To Buy In

Athenex has performed well in early trading since its market debut. It has demonstrated growing revenues, and its underwriters chose to exercise their over-allotment options in full.

We believe that the underwriters are likely to release detailed positive recommendations and analyses when the quiet period expires, resulting in at least a temporary price boost.

We recommend that investors purchase shares of Athenex before the quiet period expiration to take advantage of the potential increase in the share price; ideally, our firm has found a window of (-5,+2) days for such plays.


1 2
View single page >> |

Disclosure: I am/we are long ATNX.

Disclaimer: I wrote this article myself, and it expresses my own opinions. I am not receiving compensation for it. I have no business relationship with any ...

How did you like this article? Let us know so we can better customize your reading experience.


Leave a comment to automatically be entered into our contest to win a free Echo Show.